RANCHO CORDOVA, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing and storage of cell therapies, today said it will be participating in the 25 th Annual Roth Conference on Wednesday, March 20. The presentation by Matthew T. Plavan, Chief Executive Officer, will begin at 8:30 a.m., Pacific Daylight Time (11:30 a.m., Eastern Daylight Time). The presentation will be available through the conference website at http://wsw.com/webcast/roth27/kool/ and via the Company's website at http://www.thermogenesis.com/company/investor-relations/webcasts-calls/ About ThermoGenesis Corp. ThermoGenesis Corp. ( www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the separation, preservation and delivery of cell and tissue therapy products. These include:
- The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
- The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
CONTACT: ThermoGenesis Corp. Web site: http://www.thermogenesis.com Investor Relations +1-916-858-5107, or email@example.com